Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Financing › Details

Lytix Biopharma–SEVERAL: investment, 201704 private placement NOK60m incl NOK6m from Norwegian Cancer Society


Period Period 2017-04-20
  Predecessor Lytix Biopharma–SEVERAL: investment, 201512 capital increase NOK80m w 224.2k new shares at NOK350/share to existent + new shareholders
Organisation Money taker Lytix Biopharma AS
Products Product LTX-315 (Lytix Biopharma)
  Product 2 finance

Lytix Biopharma AS. (4/20/17). "Press Release: Lytix Biopharma Raises in Total 80 Million NOK".

Lytix Biopharma has closed the pre-IPO financing round, and is now finalizing the repair share issue.

- We were able to reach the target of raising 60 MNOK, and the repair share issue was fully subscribed and brought in 20,8 MNOK more. The proceeds for these share issues will fund the rest of the Phase I study and one or two new trials that we are planning, says Torbjørn Furuseth, CFO in Lytix.

The plan is that Lytix Biopharma will go public at the end of this year and be listed at the Nasdaq Stockholm exchange. In order to prepare for the IPO the pre-IPO was directed towards the largest Norwegian shareholders (>1%) as well as Swedish life science investors. The pre-IPO was successful and we reached the target of 60 MNOK. At the moment, we are finalizing the repair issue directed towards those not invited in the pre-IPO. The repair issue was fully subscribed and will bring in the maximum – 20,8 MNOK.

Record changed: 2017-08-28


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Lytix Biopharma AS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top